When the N-cadherin-mediated adhesion of CML cells to MSCs was interrupted with anti-N-cadherin short cyclic HAV peptide (NCDH), the CML cells gained sensitivity toward imatinib treatment. The gene discussed is CDH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.